Reference no: EM133862100
Question 1 Describe the aim and rationale for this study? (Only the first 200 words will be marked)
Question 2 Describe the study design used in the paper and outline three (3) specific measures the researchers implemented to minimise selection bias, information bias or other potential blase: (Only the first three measures will be marked)
Question 3 Describe the modified intention-to-treat (mITT) analysis used in this study and how it differs from a standard intention-to-treat (ITT) analysis.
Question 4 What impact does the modified intention-to-treat (mITT) analysis have on the results of the study?
Question 5 What was the primary outcome variable in this study, and how and when was it measured?
Question 6 Describe two (2) of the secondary outcome variables in this study and how they were measure
Question 7 Explain in two to three of sentences only the key findings of the study in relation to the primary endpoint using data from the paper to support your answer?
Question 8 Discuss two (2) specific study design elements that enhance potential external validity? (Only the first two answer will be marked)
Question 9 Describe two (2) examples of how the lack of blinding in this trial could introduce bias. (Only the first two answer will be marked)
Question 10 The study reported a statistically significant reduction in HbA1c in the intervention group. Based on findings from previous meta-analyses on cognitive behavioural therapy (CBT) for glycaemic control, compare the observed reduction in HbA1c from this study with prior evidence. Using additional sources, discuss whether this reduction is considered clinically meaningful in diabetes management guidelines. Be sure to reference any external sources used. Use data from the paper to support your answer
Question 11 The study was conducted using a fully remote, decentralised design. Discuss the strengths and limitations of this approach in terms of both internal and external validity.
Article - Randomized, Controlled Trial of a Digital Behavioral Therapeutic Application to Improve Glycemic Control in Adults With Type 2 Diabetes.